GE Healthcare has highlighted an innovative portfolio of molecular imaging technologies and agents at the 57th annual meeting of the Society of Nuclear Medicine (SNM). One example of how GE Healthcare has improved clinician’s experience for patients is through dose management. Another example of GE Healthcare’s commitment to responsible dose management is the ability to reduce injected dose by up to 50 percent compared with standard cardiac and bone protocols.

Read the full story here

Women in British Columbia will no longer have to wait weeks to find out if their abnormal mammography results are cause for worry. The screening mammography program (SMP) at BC Cancer Agency is expanding the Fast Track referral system to provide all physicians in British Columbia with access to the program designed to reduce the time between an abnormal screening mammography result and access to further diagnostic investigation.

Cleveland BioLabs, Inc. announced that the first healthy volunteers have been dosed in the second human safety study for CBLB502, a drug under development for the treatment of Acute Radiation Syndrome (ARS). CBLB502 is being developed by Cleveland BioLabs under the FDA’s Animal Efficacy Rule to treat Acute Radiation Syndrome (ARS) or radiation poisoning from any exposure to radiation such as a nuclear or radiological weapon / dirty bomb, or from a nuclear accident.

For the full story, Click Here

Oraya Therapeutics, Inc. announced that enrollment is now underway for the first ever masked and sham-controlled study to demonstrate the efficacy and safety of radiation therapy for the treatment of wet age-related macular degeneration . The groundbreaking clinical trial is being conducted at seven European sites, and will include at least 150 patients, with approximately one third of those receiving a sham exposure and the remainder receiving radiation dosing of either 16 or 24 Gray.

For the full story, Click Here

Cleveland BioLabs, Inc. announced that the U.S. Patent and Trademark Office has issued US Patent No. 7,638,485 titled “Modulating Apoptosis” covering the method of protecting a mammal from radiation using flagellin or its derivatives, including CBLB502. This patent was already granted by the nine member countries of the Eurasian Patent Organization (EAPO), and two additional nations. Cleveland BioLabs has also filed two additional new patent applications related to Protectan technology in the U.S.

For the full story, Click Here

AMICAS, Inc. has announced a new contract with Central Kentucky Radiology that will allow the latter to use AMICAS Financials(TM) to streamline their radiology billing and AMICAS RIS(TM) to gain practice management efficiencies and to further improve service delivery. Central Kentucky Radiology, a 24-radiologist practice, provides interpretation services for 14 hospitals and four imaging centers. In practice for more than 40 years, Central Kentucky Radiology provides mammography, x-ray, ultrasound, CT, MRI, and interventional radiology services.

For the full story, Click Here

The research team, from the University of Heidelberg, Department of Diagnostic and Interventional Radiology, found that a three-dimensional image of the pancreas represents an additional, valuable aid to the surgeon in the preoperative assessment of the resection of a pancreatic carcinoma. They examined ten patients with suspected pancreatic tumors prospectively using multidetector CT. Using the CT data sets, a three-dimensional image was created.

For the full story, Click Here

The American College of Radiology has challenged the validity of two studies published this week in the Archives of Internal Medicine that link the overuse of CT scans with thousands of new cancer diagnoses and deaths. At the same time, ACR acknowledged that widespread CT scan use has resulted in increased radiation exposure for Americans, and called for greater oversight and vigilance to prevent needless overuse.

For the full story, Click Here

SciClone Pharmaceuticals, Inc. has announced that patient enrollment is complete ahead of schedule for its phase 2 trial of SCV-07 — a small molecule synthetic peptide with immunomodulating properties — for the treatment of severe oral mucositis (OM) in patients with head and neck cancer. Topline results of the oral mucositis trial are expected to be announced in the first half of 2010.

Buffalo Medical Group has implemented an all-digital radiation treatment system. The group has acquired an Elektra Synergy system with image-guided radiotherapy to enable physicians to more precisely and rapidly target tumors during radiation therapy. The system uses a suite of imaging tools to give clinicians 3-D patient images. Installed at BMG’s offices on Essjay Road in Williamsville, treatments on patients began in early November.